Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tideglusib - AMO Pharma

Drug Profile

Tideglusib - AMO Pharma

Alternative Names: AMO-02; NP-031112; NP-12; Nypta; Zentylor

Latest Information Update: 17 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neuropharma
  • Developer AMO Pharma; Noscira
  • Class Antidementias; Small molecules; Thiadiazoles
  • Mechanism of Action Glycogen synthase kinase 3 beta inhibitors; Tau protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myotonic dystrophy; Progressive supranuclear palsy
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Myotonic dystrophy
  • Phase II Autistic disorder
  • Discontinued Alzheimer's disease; Progressive supranuclear palsy

Most Recent Events

  • 13 Jun 2019 AMO Pharma announces intention to submit NDA for Myotonic dystrophy
  • 13 Jun 2019 Pharmacodynamics data from a phase IIa trial in Myotonic dystrophy released by AMO Pharma
  • 13 Jun 2019 AMO Pharma plans to initiate a pivotal clinical trial for Myotonic dystrophy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top